NasdaqGM - Nasdaq Real Time Price USD

Invivyd, Inc. (IVVD)

0.9454

+0.0154

+(1.66%)

As of 3:44:12 PM EDT. Market Open.

COVID’s remaining biotech contenders navigate a dwindling market

With policy and funding evolving, companies are being forced to rethink strategies.

Pharma Voice yesterday

IVVD
+1.66%

IFRX
H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall

On Wednesday, H.C. Wainwright analyst Matthew Hedberg adjusted the price target on Invivyd Inc. (NASDAQ:IVVD) from $10 to $5, while maintaining a Buy rating. This revision follows a revenue shortfall in Q1 2025. Despite this, H.C. Wainwright believes that Invivyd is transitioning from a company solely focused on COVID-19 to a broader antibody-based infectious disease […]

Insider Monkey 5 days ago

IVVD
+1.66%
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

CANOPY assessed pemivibart safety and tolerability, antiviral immunobridging, and exploratory efficacy against COVID-19, and is the only clinical trial of an authorized or approved COVID-19 monoclonal antibody or vaccine with placebo-controlled clinical efficacy data in a contemporary, seropositive U.S. population and facing modern, immune-evasive SARS-CoV-2 virusesPemivibart demonstrated strong protection from symptomatic COVID-19 versus placebo during the 6-month on-drug period (84% relative r

GlobeNewswire 7 days ago

IVVD
+1.66%
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. NCCN joins the Infectious Disease Society of America (IDSA) that updated its COVID-19 guidelines in August 2024 to recommend the use of PEMGARDA (pemivibart) for pre-exposure prophylaxis (PrEP) in modera

GlobeNewswire 11 days ago

IVVD
+1.66%
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the updated regulatory framework for COVID-19 vaccines articulated by the Agency generally aligns with recent Invivyd Citizen Petition requestsIn contrast to vaccine boosters, monoclonal antibody (mAb) therapies, including pemivibart, underwent contemporary randomized, placebo-controlled trials to evaluate safety, immunogenicity, and exploratory efficacy in relevant, modern Americans, again

GlobeNewswire 13 days ago

IVVD
+1.66%
Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ...

Invivyd Inc (IVVD) reports a 15% reduction in operating expenses and explores new viral targets, while navigating sales transitions and regulatory hurdles.

GuruFocus.com 18 days ago

IVVD
+1.66%
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -250% and 66.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 19 days ago

IVVD
+1.66%
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales forcePEMGARDA revenue re-acceleration observed in Q2 2025 to dateInvivyd continues to target near-term profitability (1H 2025) with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of operating expensesSince Emergency Use Authorization (EUA) of PEMGARDA in March 2024, no docume

GlobeNewswire 19 days ago

IVVD
+1.66%
Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

WALTHAM, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has submitted a Citizen Petition with the U.S. Food and Drug Administration (FDA) calling on the Agency to evolve from historical approaches to the development of vaccines and monoclonal antibodies (mAbs) for COVID-19 prevention, in order to rebuild American’s trust in scientific data, public health recommendations, and preventatives, including mAbs and vaccines, when effective. Americans will need a

GlobeNewswire 20 days ago

IVVD
+1.66%
Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20, 2025, at 11:00 a.m. ET in New York, NY. In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the conference who are interested in meeting with Invivyd management should contact their H.C. Wainwr

GlobeNewswire 21 days ago

IVVD
+1.66%
Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 15, 2025, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and provide recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-an

GlobeNewswire 26 days ago

IVVD
+1.66%
What's Going On With Invivyd Stock On Monday?

Invivyd, Inc. (NASDAQ:IVVD) shares gained in the premarket session on Monday after the company disclosed a $30 million term loan facility with Silicon Valley Bank (SVB), a division of First Citizens Bank. The agreement enables future capital drawdowns upon meeting specific conditions and milestones. Bill Duke, Chief Financial Officer of Invivyd, said, “We are pleased to have secured this term loan facility ahead of important anticipated catalysts, including gaining alignment with the FDA on the

Benzinga last month

IVVD
+1.66%
Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it has signed a $30 million term loan facility with Silicon Valley Bank (SVB), a division of First Citizens Bank. The deal allows for drawdown of capital in the future if certain conditions and milestones are met. “We are pleased to have secured this term loan facility ahead of important anticipa

GlobeNewswire last month

IVVD
+1.66%
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved critical problems in healthcare, technology, and energy. Mr. Royan’s investment firm, Mithril, is a significant long-term holder of Invivyd stock, and Mr. Royan led the 2022 shareholder action that focused Invivyd on its mission to deliver protection

GlobeNewswire 2 months ago

IVVD
+1.66%
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of 40% and 2.75%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

IVVD
+1.66%

SPRB
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 million2024 year-end cash and cash equivalents of $69.3 millionContinues to target near-term (by end of 1H 2025) profitability with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of manufacturing expenses Company announced in vitro neutralizat

GlobeNewswire 2 months ago

IVVD
+1.66%
Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 2 months ago

IVVD
+1.66%
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against LP.8.1 Centers for Disease Control reports LP.8.1, XEC and KP.3.1.1 together constitute the majority of current national SARS-CoV-2 variants; current dominant variants are all susceptible to PEMGARDAPemivibart antiviral activity remains within the range of expected assay variability since Omicron BA.2; affirms structural biology within Invivyd’s unique technology and reflects consi

GlobeNewswire 2 months ago

IVVD
+1.66%
Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody

Invivyd (NasdaqGM:IVVD) has seen its share price surge by an impressive 163% over the past month, driven primarily by the positive data released from its Phase 1/2 clinical trial of VYD2311, a novel monoclonal antibody candidate against COVID-19. The clinical trial results highlighted improved efficacy and a favorable safety profile, sparking investor enthusiasm amid market conditions characterized by significant volatility due to newly imposed U.S. tariffs. While major indices like the Dow...

Simply Wall St. 2 months ago

IVVD
+1.66%
Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Invivyd, Inc. (NASDAQ:IVVD) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in the biotech space. There will always be biotech […]

Insider Monkey 3 months ago

IVVD
+1.66%

Performance Overview

Return	IVVD	S&P 500 (^GSPC)
YTD	+113.41%	+1.50%
1-Year	-47.77%	+12.99%
3-Year	-70.08%	+45.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Invivyd, Inc. (IVVD)

COVID’s remaining biotech contenders navigate a dwindling market

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ...

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

What's Going On With Invivyd Stock On Monday?

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now?

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody

Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025

Performance Overview